Degeneracy and repertoire of the human HIV-1 Gag p1777-85 CTL response

Journal of Immunology

Volumn 176, Issue 11, 2006, Pages 6690-6701

  Kan Mitchell, June ^a   Bajcz, Melissa ^a   Schaubert, Keri L ^a   Price, David A ^b   Brenchley, Jason M ^b   Asher, Tedi E ^b   Douek, Daniel C ^b   Ng, Hwee L ^c   Yang, Otto O ^d   Rinaldo Jr , Charles R ^d   Benito, Jose Miguel ^e   Bisikirska, Brygida ^a   Hegde, Ramakrishna ^a   Marincola, Franco M ^f   Boggiano, César ^g   Wilson, Dianne ^g   Abrams, Judith ^a   Blondelle, Sylvie E ^g   Wilson, Darcy B ^g,h  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^e HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^f NATIONAL INSTITUTES OF HEALTH   (United States)

^g TORREY PINES INSTITUTE FOR MOLECULAR STUDIES   (United States)

^h Mixture Sciences Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; BETA 2 MICROGLOBULIN; CD8 ANTIGEN; CYTOKINE; EPITOPE; GAG P17 PROTEIN[77-85]; GAG PROTEIN; HLA A2 ANTIGEN; INTERLEUKIN 2; PEPTIDE DERIVATIVE; PROTEIN P41; SL9 ANTIGEN; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIGEN PRESENTING CELL; ARTICLE; AUTOCRINE EFFECT; CD8+ T LYMPHOCYTE; CELL DEATH; CELL PROLIFERATION; CELL SPECIFICITY; CHIMERA; CHRONIC DISEASE; CLONE; COMBINATORIAL LIBRARY; CONTROLLED STUDY; CROSS REACTION; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; GENE SEQUENCE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOSTIMULATION; IN VITRO STUDY; INFECTION CONTROL; KNOCKOUT MOUSE; MOUSE; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

EID: 33646889142     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.176.11.6690     Document Type: Article

References (64)

1. Walker, B. D., S. Chakrabarti, B. Moss, T. J. Paradis, T. Flynn, A. G. Durno, R. S. Blumberg, J. C. Kaplan, M. S. Hirsch, and R. T. Schooley. 1987. HIV-specific cytotoxic T lymphocytes in seropositive individuals. Nature 328: 345-348.
2. Koup, R. A., J. T. Safrit, Y. Cao, C. A. Andrews, G. McLeod, W. Borkowsky, C. Farthing, and D. D. Ho. 1994. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68: 4650-4655.
3. + cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J. Virol. 68: 6103-6110.
4. Klein, M. R., C. A. van Baalen, A. M. Holwerda, S. R. Kerkhof Garde, R. J. Bende, I. P. Keet, J. K. Eeftinck-Schattenkerk, A. D. Osterhaus, H. Schuitemaker, and F. Miedema. 1995. Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics. J. Exp. Med. 181: 1365-1372.
5. Moore, C. B., M. John, I. R. James, F. T. Christiansen, C. S. Witt, and S. A. Mallal. 2002. Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level. Science 296: 1439-1443.
6. Letvih, N. L. 2005. Progress toward an HIV vaccine. Annu. Rev. Med. 56: 213-223.
7. + T-cell responses represents a major driving force of human immunodeficiency virus type 1 (HIV-1) sequence diversity and reveals constraints on HIV-1 evolution. J. Virol. 79: 13239-13249.
8. Goulder, P. J., A. K. Sewell, D. G. Lalloo, D. A. Price, J. A. Whelan, J. Evans, G. P. Taylor, G. Luzzi, P. Giangrande, R. E. Phillips, and A. J. McMichael. 1997. Patterns of immunodominance in HIV-1-specific cytotoxic T lymphocyte responses in two human histocompatibility leukocyte antigens (HLA)-identical siblings with HLA-A*0201 are influenced by epitope mutation. J. Exp. Med. 185: 1423-1433.
9. Brander, C., K. E. Hartman, A. K. Trocha, N. G. Jones, R. P. Johnson, B. Korber, P. Wemworth, S. P. Buchbinder, S. Wolinsky, B. D. Walker, and S. A. Kalams. 1998. Lack of strong immune selection pressure by the immunodominant, HLA-A*0201-restricted cytotoxic T lymphocyte response in chronic human immunodeficiency virus-1 infection. J. Clin. Invest. 101: 2559-2566.
10. Goulder, P. J., M. A. Altfeld, E. S. Rosenberg, T. Nguyen, Y. Tang, R. L. Eldridge, M. M. Addo, S. He, J. S. Mukherjee, M. N. Phillips, et al. 2001. Substantial differences in specificity of HIV-specific cytotoxic T cells in acute and chronic HIV infection. J. Exp. Med. 193: 181-194.
11. Ogg, G. S., X. Jin, S. Bonhoeffer, P. R. Dunbar, M. A. Nowak, S. Monard, J. P. Segal, Y. Cao, S. L. Rowland-Jones, V. Cerundolo, et al. 1998. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science 279: 2103-2106.
12. + T-cell effector activity in HIV primary infection. J. Clin. Invest. 104: 1431-1439.
13. Altfeld, M. A., B. Livingston, N. Reshamwala, P. T. Nguyen, M. M. Addo, A. Shea, M. Newman, J. Fikes, J. Sidney, P. Wentworth, et al. 2001. Identification of novel HLA-A2-restricted human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte epitopes predicted by the HLA-A2 supertype peptide-binding motif. J. Virol. 75: 1301-1311.
14. Goulder, P. J., C. Brander, Y. Tang, C. Tremblay, R. A. Colbert, M. M. Addo, E. S. Rosenberg, T. Nguyen, R. Allen, A. Trocha, et al. 2001. Evolution and transmission of stable CTL escape mutations in HIV infection. Nature 412: 334-338.
15. Ferrari, G., W. Neal, J. Ottinger, A. M. Jones, B. H. Edwards, P. Goepfert, M. R. Berts, R. A. Koup, S. Buchbinder, M. J. McElrath, J. Tartaglia, and K. J. Weinhold. 2004. Absence of immunodominant anti-Gag p 17 (SL9) responses among Gag CTL-positive, HIV-uninfected vaccine recipients expressing the HLA-A*0201 allele. J. Immunol. 173: 2126-2133.
16. + T cells in vitro may contribute to the protective effect of HLA-B57 in HIV-infection. Eur. J. Immunol. 35: 150-158.
17. Douek, D. C., M. R. Betts, J. M. Brenchley, B. J. Hill, D. R. Ambrozak, K. L. Ngai, N. J. Karandikar, J. P. Casazza, and R. A. Koup. 2002. A novel approach to the analysis of specificity, clonality, and frequency of HIV-specific T cell responses reveals a potential mechanism for control of viral escape. J. Immunol. 168: 3099-3104.
18. Jamieson, B. D., O. O. Yang, L. Hultin, M. A. Hausner, P. Hultin, J. Matud, K. Kunstman, S. Killian, J. Altman, K. Kommander, et al. 2003. Epitope escape mutation and decay of human immunodeficiency virus type 1-specific CTL responses. J. Immunol. 171: 5372-5379.
19. Edwards, C. T., K. J. Pfafferott, P. J. Goulder, R. E. Phillips, and E. C. Holmes. 2005. Intrapatient escape in the A*0201-restricted epitope SLYNTVATL drives evolution of human immunodeficiency virus type 1 at the population level. J. Virol. 79: 9363-9366.
20. + T cells to gut-associated lymphoid tissue during chronic infection. J. Virol. 77: 5621-5631.
21. + T cells in GALT: implications for immune control of HIV-1 infection. J. Immunol. 173: 641-648.
22. Tsomides, T. J., A. Aldovini, R. P. Johnson, B. D. Walker, R. A. Young, and H. N. Eisen. 1994. Naturally processed viral peptides recognized by cytotoxic T lymphocytes on cells chronically infected by human immunodeficiency virus type 1. J. Exp. Med. 180: 1283-1293.
23. Brander, C., O. O. Yang, N. G. Jones, Y. Lee, P. Goulder, R. P. Johnson, A. Trocha, D. Colbert, C. Hay, S. Buchbinder, et al. 1999. Efficient processing of the immunodominant, HLA-A*0201-restricted human immunodeficiency virus type 1 cytotoxic T-lymphocyte epitope despite multiple variations in the epitope flanking sequences. J. Virol. 73: 10191-10198.
24. Kan-Mitchell, J., B. Bisikirska, F. Wong-Staal, K. L. Schaubert, M. Bajcz, and M. Bereta. 2004. The HIV-1 HLA-A2-SLYNTVATL is a help-independent CTL epitope. J. Immunol. 172: 5249-5261.
25. Sewell, A. K., B. L. Booth, Jr., V. Cerundolo, R. E. Phillips, and D. A. Price. 2002. Differential processing of HLA A2-restricted HIV type 1 cytotoxic T lymphocyte epitopes. Viral Immunol. 15: 193-196.
26. 26: ttIV Molecular Immunology Database 1999. Los Alamos National Laboratory, Theoretical Biology and Biophysics, Los Alamos, NM.
27. Lee, J. K., G. Stewart-Jones, T. Dong, K. Harlos, K. Di Gleria, L. Dorrell, D. C. Douek, P. A. van der Merwe, E. Y. Jones, and A. J. McMichael. 2004. T cell cross-reactivity and conformational changes during TCR engagement. J. Exp. Med. 200: 1455-1466.
28. Livingston, B., C. Crimi, M. Newman, Y. Higashimoto, E. Appella, J. Sidney, and A. Sette. 2002. A rational strategy to design multiepitope immunogens based on multiple Th lymphocyte epitopes. J. Immunol. 168: 5499-5506.
29. Cannon, P. M., S. Matthews, N. Clark, E. D. Byles, O. Iourin, D. J. Hockley, S. M. Kingsman, and A. J. Kingsman. 1997. Structure-function studies of the human immunodeficiency virus type 1 matrix protein, p17. J. Virol. 71: 3474-3483.
30. Yokomaku, Y., H. Miura, H. Tomiyama, A. Kawana-Tachikawa, M. Takiguchi, A. Kojima, Y. Nagai, A. Iwamoto, Z. Matsuda, and K. Ariyoshi. 2004. Impaired processing and presentation of cytotoxic-T-lymphocyte (CTL) epitopes are major escape mechanisms from CTL immune pressure in human immunodeficiency virus type 1 infection. J. Virol. 78: 1324-1332.
31. HIV Immunology and HIV/SIV Vaccine Databases 2003. Los Alamos National Laboratory, Theoretical Biology and Biophysics, Los Alamos, NM.
32. + T-cell responses: relationship to viral load in untreated HIV infection. J. Virol. 75: 11983-11991.
33. Addo, M. M., X. G. Yu, A. Rathod, D. Cohen, R. L. Eldridge, D. Strick, M. N. Johnston, C. Corcoran, A. G. Wurcel, C. A. Fitzpatrick, et al. 2003. Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load. J. Virol. 77: 2081-2092.
34. Mason, D. 1998. A very high level of cross-reactivity isan essential feature of the T-cell receptor. Immunol. Today 19: 395-404.
35. Berzofsky, J. A., J. D. Ahlers, and I. M. Belyakov. 2001. Strategies for designing and optimizing new generation vaccines. Nat. Rev. Immunol. 1: 209-219.
36. McKinney, D. M., R. Skvoretz, B. D. Livingston, C. C. Wilson, M. Anders, R. W. Chesnut, A. Sette, M. Essex, V. Novitsky, and M. J. Newman. 2004. Recognition of variant HTV-1 epitopes from diverse viral subtypes by vaccine-induced CTL. J. Immunol. 173: 1941-1950.
37. Wilson, D. B., D. H. Wilson, K. Schroder, C. Pinilla, S. Blondelle, R. A. Houghten, K. C. Garcia, E. Borras, R. Martin, V. Judkowski, et al. 2004. Specificity and degeneracy of T cells. Mol. Immunol. 40: 1047-1055.
38. Yang, O. O., P. T. Sarkis, A. Trocha, S. A. Kalams, R. P. Johnson, and B. D. Walker. 2003. Impacts of avidity and specificity on the antiviral efficiency of HIV-1-specific CTL. J. Immunol. 171: 3718-3724.
39. Sarobe, P., C. D. Pendleton, T. Akatsuka, D. Lau, V. H. Engelhard, S. M. Feinstone, and J. A. Berzofsky. 1998. Enhanced in vitro potency and in vivo immunogenicity of a CTL epitope from hepatitis C virus core' protein following amino acid replacement at secondary HLA-A2.1 binding positions. J. Clin. Invest. 102: 1239-1248.
40. + T cell repertoires of H-2 class I wild-type/HLA-A2.1 and H-2 class I knockout/HLA-A2.1 transgenic mice. Int. Immunol. 14: 925-934.
41. Harrell, F. E. 2002. Regression Modeling Strategies. Springer Verlag, New York.
42. Elemento, O., and M. P. Lefranc. 2003. IMGT/PhyloGene: an on-line tool for comparative analysis of immunoglobulin and T cell receptor genes. Dev. Comp. Immunol. 27: 763-779.
43. + T cell effector activity is dictated by cognate peptide concentration. J. Immunol. 172: 6407-6417.
44. Tangri, S., G. Y. Ishioka, X. Huang, J. Sidney, S. Southwood, J. Fikes, and A. Sette. 2001. Structural features of peptide analogs of human histocompatibility leukocyte antigen class I epitopes that are more potent and immunogenic than wild-type peptide. J. Exp. Med. 194: 833-846.
45. + T cell help. J. Infect. Dis. 189: 971-983.
46. Franco, A., D. A. Tilly, I. Gramaglia, M. Croft, L. Cipolla, M. Meldal, and H. M. Grey. 2000. Epitope affinity for MHC class I determines helper requirement for CTL priming. Nat. Immunol. 1: 145-150.
47. Alexander-Miller, M. A., G. R. Leggatt, and J. A. Berzofsky. 1996. Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc. Natl. Acad. Sci. USA 93: 4102-4107.
48. Ali, A., S. Pillai, H. Ng, R. Lubong, D. D. Richman, B. D. Jamieson, Y. Ding, M. J. McElrath, J. C. Guatelli, and O. O. Yang. 2003. Broadly increased sensitivity to cytotoxic T lymphocytes resulting from Nef epitope escape mutations. J. Immunol. 171: 3999-4005.
49. Choi, E. M., J. L. Chen, L. Wooldridge, M. Salio, A. Lissina, N. Lissin, I. F. Hermans, J. D. Silk, F. Mirza, et al. 2003. High avidity antigen-specific CTL identified by CD8-independent tetramer staining. J. Immunol. 171: 5116-5123.
50. Garcia-Benayas, T., F. Blanco, J. M. Gomez-Viera, A. Barrios, V. Soriano, and J. Gonzalez-Lahoz. 2002. Lipodystrophy body-shape changes in a patient undergoing zidovudine monotherapy. AIDS. 16: 1087-1089.
51. Slifka, M. K., and J. L. Whitton. 2000. Clinical implications of dysregulated cytokine production. J. Mol. Med. 78: 74-80.
52. Haribhai, D., B. Edwards, M. L. Williams, and C. B. Williams. 2004. Functional reprogramming of the primary immune response by T cell receptor antagonism. J. Exp. Med. 200: 1371-1382.
53. Ahlers, J. D., T. Takeshita, C. D. Pendleton, and J. A. Berzofsky. 1997. Enhanced immunogenicity of HIV-1 vaccine construct by modification of the native peptide sequence. Proc. Natl. Acad. Sci. USA 94: 10856-10861.
54. Kersh, E. N., S. M. Kaech, T. M. Onami, M. Moran, E. J. Wherry, M. C. Miceli, and R. Ahmed. 2003. TCR signal transduction in antigen-specific memory CD8 T cells. J. Immunol. 170: 5455-5463.
55. Croft, M. 2003. Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? Nat. Rev. Immunol. 3: 609-620.
56. + T-cell priming regulated by cytokines of the innate immune system. Trends Mol. Med. 10: 366-371.
57. Beadling, C., and M. K. Slifka. 2005. Differential regulation of virus-specific T-cell effector functions following activation by peptide or innate cytokines. Blood 105: 1179-1186.
58. Zimmerli, S. C., A. Harari, C. Cellerai, F. Vallelian, P. A. Bart, and G. Pantaleo. 2005. HIV-1-specific IFN-γ/IL-2-secreting CD8 T cells support CD4-independent proliferation of HIV-1-specific CD8 T cells. Proc. Natl. Acad. Sci. USA 102: 7239-7244.
59. + T-cells. Blood Epub ahead of print.
60. Price, D. A., S. M. West, M. R. Betts, L. E. Ruff, J. M. Brenchley, D. R. Ambrozak, Y. Edghill-Smith, M. J. Kuroda, D. Bogdan, K. Kunstman, et al. 2004. T cell receptor recognition motifs govern immune escape patterns in acute SIV infection. Immunity 21: 793-803.
61. + T cells are hyperreactive to antigenic challenge in vitro. J. Exp. Med. 184: 2141-2151.
62. Mullbacher, A., and K. Flynn. 1996. Aspects of cytotoxic T cell memory. Immunol. Rev. 150: 113-127.
63. + T cells can be distinguished by their cytokine profiles and phenotypic markers. J. Immunol. 164: 208-216.
64. + T-cell memory. Curr. Opin. Immunol. 16: 271-276.